MaxCyte Q2 FY26 net loss narrows 28% to $8.9 million; revenue drops 15% to $7.3 million

Reuters2026/08/12 20:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MaxCyte posted Q2 2026 revenue of USD 7.3 million, down 15% from Q2 2025; net loss narrowed to USD 8.9 million.
Core revenue fell 21% to USD 6.5 million; SPL Program-related revenue rose to USD 0.8 million from USD 0.3 million.
Gross profit slipped to USD 5.6 million, cutting gross margin to 77% from 82% a year earlier.
Operating expenses dropped to USD 15.8 million from USD 21.2 million; cash, cash equivalents and investments totaled USD 141.9 million.
MaxCyte reiterated 2026 revenue guidance of USD 30 million-USD 32 million; it also disclosed a multi-platform license partnership with Genentech.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808966) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MaxCyte Q2 FY26 net loss narrows 28% to $8.9 million; revenue drops 15% to $7.3 million

You may also like

Crypto prices